Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04655976 | Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy | PHASE3 | ACTIVE NOT_RECRUITING | 758 | — | — | Dec 8, 2020 | Mar 30, 2027 | Sep 26, 2025 | 163 | United States, Argentina +22 |
OS is defined as survival from the date of randomization to the date of death by any cause.
OS is defined as survival from the date of randomization to the date of death by any cause.
| Arm | Type | Description |
|---|---|---|
| Participants receiving cobolimab+ dostarlimab+ docetaxel | EXPERIMENTAL | - |
| Participants receiving dostarlimab+ docetaxel | EXPERIMENTAL | - |
| Participants receiving docetaxel | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Cobolimab | BIOLOGICAL | Cobolimab will be administered. |
| Dostarlimab | BIOLOGICAL | Dostarlimab will be administered. |
| Docetaxel | DRUG | Docetaxel will be administered. |
Inclusion Criteria: * Participant has histologically or cytologically proven advanced or metastatic NSCLC and only squamous or non-squamous cell carcinoma. * Participant has received no more than 2 prior lines of therapy for advanced or metastatic disease, which must only include a platinum based (...